Browse the evidence

Weight loss interventions, if deemed to be necessary, should be considered carefully.

Practitioners should approach weight loss interventions with caution, considering potential risks.

The estimated health care cost offsets from clinical benefits of GLP-1RAs are projected to be $18.2 billion over 10 years.

Practitioners should consider the potential health care savings from clinical benefits of GLP-1RAs.

No significant effect of frequency was found for muscle hypertrophy.

Older adults may not experience additional muscle growth benefits from increasing resistance training frequency beyond two sessions per week.

There was no difference in mean total body weight change between IBD and non-IBD cohorts after semaglutide initiation.

Weight loss outcomes with semaglutide appear consistent regardless of IBD status.

Common complications associated with GLP-1 RA treatment include nausea, constipation, abdominal pain, and vomiting.

Healthcare providers should monitor patients for these common side effects when prescribing GLP-1 RA.

85% of adolescents report no physical activity.

Strategies are needed to promote physical activity among adolescents.

Within the diabetes support and education (DSE) group, cardiovascular disease outcomes did not differ.

DSE alone may not be sufficient to impact cardiovascular outcomes compared to intensive lifestyle interventions.

Disparities in the use of SGLT-2 inhibitors and GLP-1 receptor agonists exist based on race, sex, and socioeconomic status.

Efforts should be made to address these disparities in prescribing practices.

The American and European guidelines have similar approaches to CVD prevention but also have some differences.

Clinicians should be aware of both similarities and differences in guidelines for tailored patient care.

Systolic blood pressure was not statistically different between traditional resistance training (RT) and high velocity resistance training (HVRT) at the beginning and during 30 minutes after sessions.

Both training modalities may be equally effective in managing systolic blood pressure in this population.

Traditional recommendations for obesity treatment are largely ineffective.

Practitioners should be aware that traditional methods may not yield results.

23% of participants reported any adverse event while using GLP-1RAs, with 7% discontinuing treatment.

While GLP-1RAs are generally well-tolerated, practitioners should monitor for adverse events.

HMB demonstrated no significant effect on body mass (BM) in athletes.

Athletes should not expect HMB to significantly affect their body weight.

HMB has a small, nonsignificant effect on fat mass (FM) in athletes.

HMB may have a minimal effect on reducing fat mass, but it is not statistically significant.

Seven foods contributed 50% of total energy intake in the Mexican population aged 5 years and older.

Practitioners should focus on these key foods when addressing energy intake in dietary recommendations.

There is great heterogeneity in energy intake among different subgroups of the Mexican population.

Dietary interventions may need to be tailored to specific subgroups to be effective.

Treatment of wild-type mice with linolenic acid reduced food intake and body mass.

Using linolenic acid may help reduce food intake and body mass in certain contexts.

Treatment with semaglutide was associated with a significant odds of NAION (OR, 3.92; 95% CI, 1.02-15.02).

Clinicians should monitor for NAION in patients treated with semaglutide.

Current evidence remains insufficient to establish definitive conclusions regarding the association of semaglutide with NAION.

Further research is needed to clarify the risk of NAION with semaglutide.

Eccentric duration had no impact on rating of perceived exertion (RPE), range of motion (ROM), or barbell path.

Eccentric phase manipulation may not affect perceived exertion or movement mechanics.

The screening criteria for sarcopenic obesity include BMI, waist circumference, calf circumference, the SARC-F, and the Finger Ring test.

These criteria can guide practitioners in screening for sarcopenic obesity.

Benefits of the intervention were not evident for those entering the trial with a history of cardiovascular disease.

Practitioners should consider individual health histories when recommending lifestyle interventions.

Consumption of both dietary plant and animal protein was not related to the risk of total CHD and HTN.

Neither plant nor animal protein intake is linked to increased risk of CHD or HTN.

The risk of CHD and HTN did not change significantly with increasing dietary total protein intake from 10% to 25% of total calorie intake.

Increasing total protein intake within this range does not affect CHD or HTN risk.